샘플 요청 목록

 카트 문의
시장보고서
상품코드
2056716

신경퇴행성 질환 치료제 시장

Neurodegenerative Diseases Therapeutics
발행일: | 리서치사: 구분자 Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 387 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 9,084,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 27,253,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 신경퇴행성 질환 치료제 시장은 2032년까지 678억 달러에 이를 전망

2025년에 416억 달러로 추정되는 신경퇴행성 질환 치료제 세계 시장은 2025년부터 2032년 분석 기간 중 CAGR 7.2%로 성장하여 2032년까지 678억 달러에 이를 것으로 예상되고 있습니다. 본 보고서로 분석 대상이 되고 있는 부문 중 하나인 면역 조절제는 7.8%의 CAGR을 기록해, 분석 기간 종료까지 285억 달러에 이를 것으로 예상되고 있습니다. 도파민 작용제 부문의 성장률은 분석 기간 중 CAGR 6.6%이 된다고 추정되고 있습니다.

미국 시장은 129억 달러로 추계되는 한편, 중국은 CAGR 11.4%를 나타낼 것으로 예측됩니다

미국 신경퇴행성 질환 치료제 시장은 2025년에 129억 달러로 추계되고 있습니다. 세계 제 2위 경제 규모를 자랑하는 중국은 2025년부터 2032년 분석 기간 중 CAGR 11.4%로 성장을 지속하여, 2032년까지 시장 규모가 169억 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있어 분석 기간 중에 각각 CAGR 4.0% 및 7.1%를 나타낼 것으로 예측됩니다. 유럽내에서는 독일이 약 5.2%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

세계의 신경퇴행성 질환 치료제 시장-주요 촉진요인과 동향 개요

신경퇴행성 질환 치료제는 진행성 신경계 기능 장애를 특징으로 하는 질환의 관리 및 병세 진행을 잠재적으로 변화시키는 것을 목적으로 하는 광범위한 치료법을 포함하고 있습니다. 이러한 질환에는 알츠하이머병, 파킨슨병, 헌팅턴병, 근위축성 측삭 경화증(ALS) 등이 포함됩니다. 이러한 치료제의 주요 목적은 증상 완화, 삶의 질 향상, 그리고 경우에 따라 질병의 진행을 늦추는 것입니다. 치료법은 콜린에스테라제 억제제나 도파민 작용제 등의 약리학적 개입부터 유전자 치료나 신경 보호제와 같은 첨단 접근법까지 다양합니다.

지난 10년 동안 신경퇴행성 질환 치료 분야에서는 질환 메커니즘에 대한 이해가 깊어지고 기술 혁신이 이루어짐에 따라 눈부신 진전이 있었습니다. 기존의 약물 치료에 더해, 이러한 질환의 근본적인 병태를 표적으로 하는 새로운 접근법이 도입되고 있습니다. 예를 들어, 아밀로이드 베타 플라크를 제거하도록 설계된 단일클론 항체는 알츠하이머병에서 유망한 결과를 보여주고 있는 반면, 헌팅턴병과 같은 질환에서는 유전자 변이를 교정할 가능성을 지닌 유전자 치료가 검토되고 있습니다. 또한, 조기 진단을 위한 바이오마커의 활용과 맞춤형 의료 접근법이 점점 더 널리 보급되면서, 환자에게 더욱 맞춤화된 효과적인 치료 전략이 가능해졌습니다. 임상시험 및 연구 활동은 지속적으로 확대되고 있으며, 신경퇴행성 질환의 관리 방식을 혁신적으로 변화시킬 잠재력을 지닌 새로운 치료법 파이프라인을 제공합니다.

신경퇴행성 질환 치료제 시장의 성장은 기술 발전, 신경퇴행성 질환 유병률 증가, 연구개발 투자 확대 등 여러 요인에 의해 주도되고 있습니다. 생명공학 및 분자생물학의 혁신은 CRISPR 기반 유전자 편집이나 줄기세포 치료와 같은 최첨단 치료법의 길을 열어주었으며, 이러한 치료법들은 해당 질환의 근본 원인을 해결할 가능성을 지니고 있습니다. 전 세계적인 고령화는 신경퇴행성 질환의 발병률 증가에 기여하고 있으며, 이에 따라 효과적인 치료법에 대한 수요가 높아지고 있습니다. 게다가 제약 회사와 정부 기관의 막대한 투자가 새로운 치료법 개발을 뒷받침하고 있습니다. 학계, 산업계, 규제 당국 간의 협력을 통해 새로운 치료법의 발견과 승인 속도가 빨라지고 있습니다. 이러한 요인들에 더해, 질환 메커니즘에 대한 이해가 깊어지고 정밀의학(Precision Medicine)이 등장함에 따라 신경퇴행성 질환 치료제 시장은 강력한 성장세를 이어가고 있으며, 전 세계 환자들에게 치료 성과가 개선될 것으로 기대되고 있습니다.

부문:

약제 클래스별(면역조절제, 도파민 작용제, 코린에스테라제 억제제, 데카복실레이스 억제제, 기타 약제 클래스), 질환 유형(다발성 경화증, 알츠하이머 병, 파킨슨병, 기타 질환 유형), 유통 채널(드럭스토어 및 소매 약국, 병원 약국, 온라인 약국)

주요 기업

  • AbbVie, Inc.
  • Alector, Inc.
  • AstraZeneca PLC
  • Biohaven, Ltd.
  • Bristol-Myers Squibb Company
  • Coya Therapeutics
  • Denali Therapeutics, Inc.
  • Eli Lilly and Company
  • Genentech, Inc.
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Les Laboratoires Servier
  • MD Biosciences, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Prothena Corporation PLC

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 26.06.17

Global Neurodegenerative Diseases Therapeutics Market to Reach US$67.8 Billion by 2032

The global market for Neurodegenerative Diseases Therapeutics estimated at US$41.6 Billion in the year 2025, is expected to reach US$67.8 Billion by 2032, growing at a CAGR of 7.2% over the analysis period 2025-2032. Immunomodulators, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$28.5 Billion by the end of the analysis period. Growth in the Dopamine Agonists segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.9 Billion While China is Forecast to Grow at 11.4% CAGR

The Neurodegenerative Diseases Therapeutics market in the U.S. is estimated at US$12.9 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$16.9 Billion by the year 2032 trailing a CAGR of 11.4% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Neurodegenerative Diseases Therapeutics Market - Key Drivers and Trends Summarized

Neurodegenerative diseases therapeutics encompass a broad array of treatments aimed at managing and potentially altering the course of diseases characterized by progressive nervous system dysfunction. These diseases include Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS), among others. The primary focus of these therapeutics is to alleviate symptoms, improve quality of life, and, in some cases, slow disease progression. Treatments range from pharmacological interventions, such as cholinesterase inhibitors and dopamine agonists, to advanced approaches like gene therapy and neuroprotective agents.

Over the past decade, the field of neurodegenerative disease therapeutics has witnessed remarkable advancements, propelled by a deeper understanding of disease mechanisms and technological innovations. Traditional pharmacological treatments have been supplemented by novel approaches targeting the underlying pathology of these diseases. For instance, monoclonal antibodies designed to clear amyloid-beta plaques have shown promise in Alzheimer's disease, while gene therapies are being explored for their potential to correct genetic mutations in conditions like Huntington's disease. Additionally, the use of biomarkers for early diagnosis and personalized medicine approaches are becoming increasingly prevalent, allowing for more tailored and effective treatment strategies. Clinical trials and research efforts continue to expand, providing a pipeline of potential new therapies that could transform the management of neurodegenerative diseases.

The growth in the neurodegenerative diseases therapeutics market is driven by several factors, including technological advancements, increasing prevalence of neurodegenerative disorders, and heightened investment in research and development. Innovations in biotechnology and molecular biology have paved the way for cutting-edge treatments such as CRISPR-based gene editing and stem cell therapies, which hold the promise of addressing the root causes of these diseases. The aging global population is contributing to a higher incidence of neurodegenerative conditions, thereby increasing the demand for effective treatments. Furthermore, substantial investments from pharmaceutical companies and government agencies are fueling the development of new therapeutics. Collaborative efforts between academia, industry, and regulatory bodies are accelerating the pace of discovery and approval of new treatments. These factors, combined with a growing understanding of disease mechanisms and the advent of precision medicine, are driving the robust expansion of the neurodegenerative diseases therapeutics market, offering hope for improved outcomes for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Neurodegenerative Diseases Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors, Other Drug Classes); Disease Type (Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease, Other Disease Types); Distribution Channel (Drug Store & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • AbbVie, Inc.
  • Alector, Inc.
  • AstraZeneca PLC
  • Biohaven, Ltd.
  • Bristol-Myers Squibb Company
  • Coya Therapeutics
  • Denali Therapeutics, Inc.
  • Eli Lilly and Company
  • Genentech, Inc.
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Les Laboratoires Servier
  • MD Biosciences, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Prothena Corporation PLC

WHAT SETS THIS REPORT APART FROM OTHERS?

Validated Sources - Human-curated validation and ranking of original source content, not AI LLM-generated synthetic content which dominates the internet today and has become a quick fix for most published research reports these days. Unlike most other published sources, our customers have access to full-stack source content. Our report draws from "real intelligence" balancing the power of AI against the risks of synthetically generated content and resulting biases. Customers have access to the source feeds.

Domain Expert Insights - Domain expert insights curated from enterprise, industry, academia, and government, consolidated from multilingual multimedia formats of text, voice, and images comprise a significant resource. Customers can request access to the pool of domain experts we track for this research project. We track 43 domain experts and their insights as part of this research project. Our customers may access our online tracker.

Annual subscription - Recommended for maximum value for your research dollar. Provides one additional full update during the 12 months and access to our research portal and interactive 10-user peer-to-peer collaboration drawing from our entire stack of validated project data which is updated on a weekly basis. Platform also enables adding enterprise data or third-party licensed content to build bespoke versions. Includes competitor tracking of up to 50 companies featured in the report.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Neurodegenerative Diseases Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Neurodegenerative Diseases Drives Demand for Therapeutics
    • Advancements in Biomarker Research Propel Growth in Neurodegenerative Therapeutics Market
    • Growing Awareness of Alzheimer's and Parkinson's Diseases Spurs Market Demand
    • Innovations in Gene Therapy Generate Market Interest and Drive Adoption
    • Expansion of Biopharmaceutical Sector Enhances Development of Novel Treatments
    • Rising Prevalence of Comorbid Conditions Sustains Demand for Comprehensive Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurodegenerative Diseases Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Decarboxylase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Decarboxylase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Multiple Sclerosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Multiple Sclerosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Multiple Sclerosis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Parkinson's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 44: USA Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: USA Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: USA 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 47: USA Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: USA Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Canada Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: Canada 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Canada Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Canada 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Canada Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Canada 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • JAPAN
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Japan Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Japan 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Japan Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: Japan 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Japan Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Japan 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • CHINA
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: China Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: China 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 71: China Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: China Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: China 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 74: China Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: China Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: China 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • EUROPE
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Europe Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • FRANCE
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: France Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: France 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 92: France Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: France Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: France 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 95: France Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: France Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: France 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • GERMANY
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Germany Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Germany 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Germany Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Germany 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Germany Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Germany 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Italy Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Italy 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Italy Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Italy 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Italy Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Italy 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: UK Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: UK 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 119: UK Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: UK Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: UK 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 122: UK Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: UK Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: UK 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Spain Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Spain 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Spain Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Spain 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Spain Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Spain 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Russia Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Russia 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Russia Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Russia 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Russia Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Russia 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Rest of Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Rest of Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Rest of Europe 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
  • INDIA
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 153: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 158: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 161: Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 164: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Argentina Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Argentina 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 167: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Argentina Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Argentina 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 170: Argentina Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Argentina Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Argentina 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 173: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Brazil Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Brazil 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 176: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Brazil Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Brazil 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 179: Brazil Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Brazil Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Brazil 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 182: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Mexico Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Mexico 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 185: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Mexico Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Mexico 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 188: Mexico Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Mexico Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Mexico 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 191: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 194: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 197: Rest of Latin America Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Rest of Latin America Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Rest of Latin America 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 200: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 201: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 203: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 206: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 209: Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 212: Iran Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Iran Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Iran 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 215: Iran Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Iran Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Iran 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 218: Iran Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Iran Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Iran 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 221: Israel Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Israel Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Israel 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 224: Israel Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Israel Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Israel 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 227: Israel Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Israel Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Israel 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 230: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Saudi Arabia Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Saudi Arabia 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 233: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Saudi Arabia Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Saudi Arabia 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 236: Saudi Arabia Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Saudi Arabia Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Saudi Arabia 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 239: UAE Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: UAE Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: UAE 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 242: UAE Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: UAE Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: UAE 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 245: UAE Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: UAE Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: UAE 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 248: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 251: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Rest of Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Rest of Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 254: Rest of Middle East Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Rest of Middle East Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Rest of Middle East 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032
  • AFRICA
    • Neurodegenerative Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 257: Africa Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Africa Historic Review for Neurodegenerative Diseases Therapeutics by Drug Class - Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Africa 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunomodulators, Dopamine Agonists, Cholinesterase Inhibitors, Decarboxylase Inhibitors and Other Drug Classes for the Years 2020, 2026 & 2032
    • TABLE 260: Africa Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Africa Historic Review for Neurodegenerative Diseases Therapeutics by Distribution Channel - Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Africa 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2020, 2026 & 2032
    • TABLE 263: Africa Recent Past, Current & Future Analysis for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Africa Historic Review for Neurodegenerative Diseases Therapeutics by Disease Type - Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Africa 13-Year Perspective for Neurodegenerative Diseases Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Multiple Sclerosis Disease, Alzheimer's Disease, Parkinson's Disease and Other Disease Types for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기